Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
976 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus Infections (AIDS) - Pipeline Review, H2 2016, provides an overview of the Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline landscape. HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus Infections (AIDS) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 17, 43, 45, 2, 108, 75 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 15, 15, 51 and 67 molecules, respectively. Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 10 Human Immunodeficiency Virus (HIV) Infections (AIDS) Overview 11 Therapeutics Development 12 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics under Development by Companies 14 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics under Investigation by Universities/Institutes 27 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Products Glance 33 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Products under Development by Companies 37 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Products under Investigation by Universities/Institutes 57 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development 67 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment 214 Drug Profiles 244 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects 864 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products 912 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones 919 Appendix 930
List of Tables
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2016 57 Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS) - Comparative Analysis, H2 2016 58 Number of Products under Development by Companies, H2 2016 60 Number of Products under Development by Companies, H2 2016 (Contd..1) 61 Number of Products under Development by Companies, H2 2016 (Contd..2) 62 Number of Products under Development by Companies, H2 2016 (Contd..3) 63 Number of Products under Development by Companies, H2 2016 (Contd..4) 64 Number of Products under Development by Companies, H2 2016 (Contd..5) 65 Number of Products under Development by Companies, H2 2016 (Contd..6) 66 Number of Products under Development by Companies, H2 2016 (Contd..7) 67 Number of Products under Development by Companies, H2 2016 (Contd..8) 68 Number of Products under Development by Companies, H2 2016 (Contd..9) 69 Number of Products under Development by Companies, H2 2016 (Contd..10) 70 Number of Products under Development by Companies, H2 2016 (Contd..11) 71 Number of Products under Investigation by Universities/Institutes, H2 2016 72 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 73 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 74 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 75 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 76 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 77 Comparative Analysis by Late Stage Development, H2 2016 78 Comparative Analysis by Clinical Stage Development, H2 2016 79 Comparative Analysis by Early Stage Development, H2 2016 80 Comparative Analysis by Unknown Stage Development, H2 2016 81 Products under Development by Companies, H2 2016 82 Products under Development by Companies, H2 2016 (Contd..1) 83 Products under Development by Companies, H2 2016 (Contd..2) 84 Products under Development by Companies, H2 2016 (Contd..3) 85 Products under Development by Companies, H2 2016 (Contd..4) 86 Products under Development by Companies, H2 2016 (Contd..5) 87 Products under Development by Companies, H2 2016 (Contd..6) 88 Products under Development by Companies, H2 2016 (Contd..7) 89 Products under Development by Companies, H2 2016 (Contd..8) 90 Products under Development by Companies, H2 2016 (Contd..9) 91 Products under Development by Companies, H2 2016 (Contd..10) 92 Products under Development by Companies, H2 2016 (Contd..11) 93 Products under Development by Companies, H2 2016 (Contd..12) 94 Products under Development by Companies, H2 2016 (Contd..13) 95 Products under Development by Companies, H2 2016 (Contd..14) 96 Products under Development by Companies, H2 2016 (Contd..15) 97 Products under Development by Companies, H2 2016 (Contd..16) 98 Products under Development by Companies, H2 2016 (Contd..17) 99 Products under Development by Companies, H2 2016 (Contd..18) 100 Products under Development by Companies, H2 2016 (Contd..19) 101 Products under Investigation by Universities/Institutes, H2 2016 102 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 103 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 104 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 105 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 106 Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 107 Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 108 Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 109 Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 110 Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 111 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H2 2016 112 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H2 2016 113 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Advanced Genetic Systems Inc, H2 2016 114 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Akshaya Bio Inc, H2 2016 115 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AlbaJuna Therapeutics, H2 2016 116 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Allergan Plc, H2 2016 117 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altor BioScience Corp, H2 2016 118 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altravax Inc, H2 2016 119 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amarna Therapeutics BV, H2 2016 120 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by American Gene Technologies International Inc, H2 2016 121 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amunix Operating Inc, H2 2016 122 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Antigen Express Inc, H2 2016 123 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aphios Corp, H2 2016 124 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Apotex Inc, H2 2016 125 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Argos Therapeutics Inc, H2 2016 126 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Arno Therapeutics Inc, H2 2016 127 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Atreca Inc, H2 2016 128 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by B Cell Design SAS, H2 2016 129 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by BioClonetics Immunotherapeutics Inc, H2 2016 130 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biological Mimetics Inc, H2 2016 131 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biosantech SA, H2 2016 132 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biotron Ltd, H2 2016 133 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 134 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bolder Biotechnology Inc, H2 2016 135 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bristol-Myers Squibb Company, H2 2016 136 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by C4X Discovery Holdings PLC, H2 2016 137 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Calimmune Inc, H2 2016 138 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by CEL-SCI Corp, H2 2016 139 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Celgene Corp, H2 2016 140 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Celldex Therapeutics Inc, H2 2016 141 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 142 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by CompleGen Inc, H2 2016 143 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ConjuChem LLC, H2 2016 144 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 145 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Critical Outcome Technologies Inc, H2 2016 146 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Curevac AG, H2 2016 147 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Cytodyn Inc, H2 2016 148 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 149 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Enzo Biochem Inc, H2 2016 150 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by EpiVax Inc, H2 2016 151 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by eTheRNA Immunotherapies NV, H2 2016 152 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Etubics Corp, H2 2016 153 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Evofem Inc, H2 2016 154 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by FIT Biotech Oy, H2 2016 155 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Formune SL, H2 2016 156 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Fountain Biopharma Inc, H2 2016 157 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Frontier Biotechnologies Co Ltd, H2 2016 158 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Galmed Pharmaceuticals Ltd, H2 2016 159 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GeneCure LLC, H2 2016 160 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GeoVax Labs Inc, H2 2016 161 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Gilead Sciences Inc, H2 2016 162 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GlaxoSmithKline Plc, H2 2016 163 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Globeimmune Inc, H2 2016 164 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GW Pharmaceuticals Plc, H2 2016 165 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by H-Phar SA, H2 2016 166 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 167 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 168 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Heat Biologics Inc, H2 2016 169 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ID Pharma Co Ltd, H2 2016 170 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by IGXBio Inc, H2 2016 171 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immune Response BioPharma Inc, H2 2016 172 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immune Therapeutics Inc, H2 2016 173 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ImmunoClin Corp, H2 2016 174 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immunocore Ltd, H2 2016 175 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immunotope Inc, H2 2016 176 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ImQuest Life Sciences Inc, H2 2016 177 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by InnaVirVax SA, H2 2016 178 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Innovative Targeting Solutions Inc, H2 2016 179 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 180 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Japan Tobacco Inc, H2 2016 181 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Johnson & Johnson, H2 2016 182 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 183 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by KPI Therapeutics Inc, H2 2016 184 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Kymab Ltd, H2 2016 185 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Longevity Biotech Inc, H2 2016 186 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by MacroGenics Inc, H2 2016 187 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Medestea Research & Production SpA, H2 2016 188 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Medivir AB, H2 2016 189 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Merck & Co Inc, H2 2016 190 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Mologen AG, H2 2016 191 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Mymetics Corp, H2 2016 192 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Myrexis Inc, H2 2016 193 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by NanoViricides Inc, H2 2016 194 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Navigen Pharmaceuticals Inc, H2 2016 195 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by NeED Pharma srl, H2 2016 196 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by New World Laboratories Inc, H2 2016 197 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Novartis AG, H2 2016 198 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Omeros Corp, H2 2016 199 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Oncolys BioPharma Inc, H2 2016 200 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by OncoNOx ApS, H2 2016 201 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Oncovir Inc, H2 2016 202 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Orbis Biosciences Inc, H2 2016 203 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Osel Inc, H2 2016 204 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by OyaGen Inc, H2 2016 205 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PaxVax Inc, H2 2016 206 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 207 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Pfizer Inc, H2 2016 208 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Pharis Biotec GmbH, H2 2016 209 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PharmatrophiX Inc, H2 2016 210 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Phoenix Biotechnology Inc, H2 2016 211 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PlantForm Corp, H2 2016 212 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Profectus BioSciences Inc, H2 2016 213 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by RAPID Pharmaceuticals AG, H2 2016 214 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ReceptoPharm Inc, H2 2016 215 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Recombio SL, H2 2016 216 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Relmada Therapeutics Inc, H2 2016 217 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Rodos BioTarget GmbH, H2 2016 218 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 219 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sangamo BioSciences Inc, H2 2016 220 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sanofi, H2 2016 221 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sanofi Pasteur SA, H2 2016 222 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Savoy Pharmaceuticals Inc, H2 2016 223 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Serometrix LLC, H2 2016 224 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sigma-Tau SpA, H2 2016 225 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sirenas Marine Discovery LLC, H2 2016 226 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Solon Eiendom ASA, H2 2016 227 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Spider Biotech, H2 2016 228 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 229 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, H2 2016 230 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Starpharma Holdings Ltd, H2 2016 231 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sumagen Co Ltd, H2 2016 232 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Susavion Biosciences Inc, H2 2016 233 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Taiga Biotechnologies Inc, H2 2016 234 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TaiMed Biologics Inc, H2 2016 235 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Takara Bio Inc, H2 2016 236 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 237 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TechnoVax Inc, H2 2016 238 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TeneoBio Inc, H2 2016 239 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TetraLogic Pharmaceuticals, H2 2016 240 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 241 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TGV-Laboratories, H2 2016 242 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Theratechnologies Inc, H2 2016 243 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Theravectys SA, H2 2016 244 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Tomegavax Inc, H2 2016 245 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Transgene Biotek Ltd, H2 2016 246 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TVAX Biomedical Inc, H2 2016 247 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by United Biomedical Inc, H2 2016 248 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vaccibody AS, H2 2016 249 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vault Pharma Inc, H2 2016 250 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by VDA Pharma Inc, H2 2016 251 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by VG Life Sciences Inc, H2 2016 252 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vichem Chemie Research Ltd, H2 2016 253 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ViiV Healthcare Ltd, H2 2016 254 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Viriom Ltd, H2 2016 255 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ViroStatics srl, H2 2016 256 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by XL-protein GmbH, H2 2016 257 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 258 Assessment by Monotherapy Products, H2 2016 259 Assessment by Combination Products, H2 2016 260 Number of Products by Stage and Target, H2 2016 262 Number of Products by Stage and Mechanism of Action, H2 2016 274 Number of Products by Stage and Route of Administration, H2 2016 286 Number of Products by Stage and Molecule Type, H2 2016 288 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H2 2016 909 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..1), H2 2016 910 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..2), H2 2016 911 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..3), H2 2016 912 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..4), H2 2016 913 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..5), H2 2016 914 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..6), H2 2016 915 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..7), H2 2016 916 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..8), H2 2016 917 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..9), H2 2016 918 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..10), H2 2016 919 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..11), H2 2016 920 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..12), H2 2016 921 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..13), H2 2016 922 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..14), H2 2016 923 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..15), H2 2016 924 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..16), H2 2016 925 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..17), H2 2016 926 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..18), H2 2016 927 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..19), H2 2016 928 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..20), H2 2016 929 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..21), H2 2016 930 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..22), H2 2016 931 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..23), H2 2016 932 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..24), H2 2016 933 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..25), H2 2016 934 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..26), H2 2016 935 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..27), H2 2016 936 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..28), H2 2016 937 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..29), H2 2016 938 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..30), H2 2016 939 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..31), H2 2016 940 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..32), H2 2016 941 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..33), H2 2016 942 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..34), H2 2016 943 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..35), H2 2016 944 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..36), H2 2016 945 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..37), H2 2016 946 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..38), H2 2016 947 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..39), H2 2016 948 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..40), H2 2016 949 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..41), H2 2016 950 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..42), H2 2016 951 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..43), H2 2016 952 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..44), H2 2016 953 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..45), H2 2016 954 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..46), H2 2016 955 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..47), H2 2016 956 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H2 2016 957 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..1), H2 2016 958 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..2), H2 2016 959 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..3), H2 2016 960 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..4), H2 2016 961 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..5), H2 2016 962 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..6), H2 2016 9
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
